NUVB - Nuvation Bio Inc. Stock Price, Fair Value and News

3.32USD-0.09 (-2.64%)Delayed

Market Summary

USD3.32-0.09

Delayed

-2.64%

NUVB Stock Price

View Fullscreen

NUVB RSI Chart

NUVB Valuation

Market Cap

820.6M

Price/Earnings (Trailing)

-11.92

Price/Sales (Trailing)

30.66

EV/EBITDA

-11.45

Price/Free Cashflow

-12.74

NUVB Price/Sales (Trailing)

NUVB Profitability

EBT Margin

-257.33%

Return on Equity

-11.59%

Return on Assets

-11.23%

Free Cashflow Yield

-7.85%

NUVB Fundamentals

NUVB Revenue

Revenue (TTM)

26.8M

Rev. Growth (Yr)

43.2%

Rev. Growth (Qtr)

1.52%

NUVB Earnings

Earnings (TTM)

-68.9M

Earnings Growth (Yr)

31.92%

Earnings Growth (Qtr)

-7.29%

Breaking Down NUVB Revenue

Last 7 days

2.2%

Last 30 days

23.4%

Last 90 days

91.9%

Trailing 12 Months

107.5%

How does NUVB drawdown profile look like?

NUVB Financial Health

Current Ratio

38.58

NUVB Investor Care

Shares Dilution (1Y)

12.96%

Diluted EPS (TTM)

-0.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	26.8M	0	0	0
2023	11.5M	16.7M	21.1M	24.6M
2022	3.5M	3.5M	4.8M	7.4M
2021	1.9M	2.1M	2.5M	3.0M
2020	1.5M	1.6M	1.8M	1.9M
2019	0	0	0	1.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Nuvation Bio Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 09, 2024	wang junyuan jerry	acquired	-	-	1,378,990	ceo, anheart therapeutics ltd.
Apr 09, 2024	wang junyuan jerry	acquired	-	-	550,758	ceo, anheart therapeutics ltd.
Apr 09, 2024	cui xiangmin	acquired	-	-	4,183,000	-
Apr 09, 2024	cui xiangmin	acquired	-	-	314,106	-
Apr 09, 2024	cui xiangmin	acquired	-	-	1,675,240	-
Sep 21, 2023	nodelman oleg	bought	72,138	1.3611	53,000	-
Sep 20, 2023	nodelman oleg	bought	159,490	1.362	117,100	-
Sep 19, 2023	nodelman oleg	bought	6,460,640	1.2562	5,143,000	-
Feb 21, 2023	nodelman oleg	bought	72,138	1.3611	53,000	-
Feb 20, 2023	nodelman oleg	bought	159,490	1.362	117,100	-

Which funds bought or sold NUVB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Ikarian Capital, LLC	reduced	-48.21	458,640	2,305,150	0.25%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.92	17,104	53,311	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-34.51	151,635	413,697	-%
May 16, 2024	AWM Investment Company, Inc.	unchanged	-	2,875,500	4,914,000	0.64%
May 15, 2024	Redmile Group, LLC	unchanged	-	6,456,050	11,032,900	0.41%
May 15, 2024	BOOTHBAY FUND MANAGEMENT, LLC	reduced	-39.24	183,384	578,083	0.01%
May 15, 2024	Tower Research Capital LLC (TRC)	added	94.92	47,890	60,839	-%
May 15, 2024	Sio Capital Management, LLC	new	-	4,863,880	4,863,880	1.45%
May 15, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	unchanged	-	64,666	80,666	-%
May 15, 2024	RBF Capital, LLC	reduced	-3.44	325,289	570,297	0.03%

Are Funds Buying or Selling NUVB?

Are funds buying NUVB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NUVB

No. of Funds

Unveiling Nuvation Bio Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 26, 2024	hung david	27.7%	61,269,498	SC 13D/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 29, 2024	blackrock inc.	5.9%	12,882,429	SC 13G
Feb 14, 2023	deep track capital, lp	3.76%	8,221,188	SC 13G/A
Feb 13, 2023	blackrock inc.	5.0%	10,996,735	SC 13G
Feb 13, 2023	omega fund v, l.p.	6.9%	15,072,340	SC 13D/A
Feb 09, 2023	vanguard group inc	4.55%	9,932,441	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Jun 23, 2022	deep track capital, lp	5.26%	11,471,281	SC 13G
Feb 11, 2022	castle creek arbitrage, llc	10%	215,426	SC 13G/A

Recent SEC filings of Nuvation Bio Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
Apr 26, 2024	10-K/A	Annual Report
Apr 18, 2024	S-8	Employee Benefits Plan
Apr 11, 2024	3	Insider Trading
Apr 11, 2024	3	Insider Trading
Apr 11, 2024	4	Insider Trading
Apr 11, 2024	4	Insider Trading
Apr 11, 2024	4	Insider Trading
Apr 10, 2024	8-K	Current Report

Peers (Alternatives to Nuvation Bio Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Nuvation Bio Inc. News

Latest updates

Nuvation Bio Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	1.5%	7,130,000	7,023,000	6,523,000	6,086,000	4,979,000	3,522,500	2,127,000	841,000	958,000	902,000	847,000	776,000	438,000	459,000	445,000	522,000	519,000	-
Operating Expenses	-3.0%	20,199,000	20,831,000	26,339,000	26,131,000	26,521,000	24,334,500	29,338,000	37,870,000	28,192,000	29,609,000	22,791,000	20,434,000	20,484,000	13,768,000	11,546,000	9,017,000	9,220,000	-
S&GA Expenses	-100.0%	-	5,480,000	7,778,000	7,541,000	7,734,000	7,464,000	8,044,000	8,948,000	7,463,000	7,607,000	5,669,000	6,400,000	4,605,000	4,432,000	2,919,000	1,672,000	1,925,000	-
R&D Expenses	-16.3%	12,842,000	15,351,000	18,561,000	18,590,000	18,787,000	16,870,500	21,294,000	28,922,000	20,729,000	22,002,000	17,122,000	14,034,000	15,879,000	9,336,000	8,627,000	7,345,000	7,295,000	-
EBITDA Margin	16.5%	-2.56	-3.07	-3.91	-5.40	-9.10	-13.96	-22.43	-29.05	-25.13	-29.25	-29.69	-30.18	-28.54	-21.37	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-7.3%	-14,792,000	-13,787,000	-19,649,000	-20,640,000	-21,726,000	-20,845,000	-27,203,000	-34,858,000	-21,293,000	-25,134,000	-21,979,000	-19,333,000	-20,402,000	-13,280,000	-11,034,000	-8,599,000	-8,746,000	-
EBT Margin	16.4%	-2.57	-3.08	-3.93	-5.41	-9.12	-13.99	-22.47	-29.10	-25.19	-29.31	-29.76	-30.24	-28.60	-21.42	-	-	-	-
Net Income	-7.3%	-14,792,000	-13,787,000	-19,649,000	-20,640,000	-21,726,000	-20,845,000	-27,203,000	-34,858,000	-21,293,000	-25,134,000	-21,979,000	-19,333,000	-20,402,000	-7,299,008	-11,034,000	-8,599,000	-8,746,000	-
Net Income Margin	16.4%	-2.57	-3.08	-3.93	-5.41	-9.12	-13.99	-22.47	-29.10	-25.19	-29.31	-27.39	-27.42	-25.39	-21.42	-	-	-	-
Free Cashflow	-4.5%	-15,702,000	-15,030,000	-16,284,000	-17,614,000	-19,414,000	-16,283,000	-28,206,000	-27,032,000	-25,043,000	-23,596,000	-13,262,000	-16,944,000	-14,844,000	-13,034,000	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q2	2019Q4
Assets	-1.3%	613	621	631	641	657	672	686	720	752	776	798	814	832	222	145	146	133	121
Current Assets	-1.4%	608	616	625	637	653	667	681	714	748	772	797	813	831	221	2.00	2.00	-	120
Cash Equivalents	-19.1%	35.00	43.00	24.00	50.00	30.00	101	139	102	106	132	345	450	639	30.00	8.00	9.00	-	3.00
Net PPE	-4.3%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	1.00
Liabilities	16.6%	19.00	16.00	19.00	17.00	16.00	17.00	19.00	27.00	28.00	30.00	28.00	25.00	26.00	7.00	1.00	0.00	2.00	3.00
Current Liabilities	12.8%	16.00	14.00	16.00	13.00	13.00	13.00	14.00	21.00	21.00	17.00	13.00	10.00	10.00	7.00	-	0.00	-	3.00
Shareholder's Equity	-1.8%	594	605	612	625	641	655	668	693	724	746	769	789	806	215	92.00	103	0.00	118
Retained Earnings	-4.3%	-357	-342	-329	-309	-288	-267	-246	-219	-184	-162	138	116	-96.36	-75.95	-10.92	-4.18	0.00	-34.30
Additional Paid-In Capital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23.00	16.00	0.00	0.00	-
Shares Outstanding	0.0%	219	219	219	219	219	219	218	218	218	218	218	218	218	149	-	-	-	-
Float	-	-	-	-	261,250	-	-	-	468,976	-	-	-	1,340	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-4.5%	-15,702	-15,030	-16,170	-17,500	-19,300	-16,169	-28,092	-26,918	-24,929	-23,482	-13,148	-16,830	-14,730	-12,937	-8,038	-6,836	-8,718	-
Share Based Compensation	35.4%	5,041	3,722	5,431	5,523	4,837	4,988	2,940	4,787	3,577	2,800	2,749	2,153	1,566	1,125	348	389	340	-
Cashflow From Investing	-77.3%	7,542	33,163	-9,592	37,346	-51,996	-21,829	106,369	-15,532	-5,551	-189,264	-91,722	-172,598	-1,085	-	6,517	10,820	10,608	-
Cashflow From Financing	-82.5%	21.00	120	77.00	133	298	407	258	-3,602	4,264	538	-32.00	57.00	624,964	66,295	73,040	3.00	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NUVB Income Statement

2024-03-31

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 12,842	$ 18,787
General and administrative	7,357	7,734
Total operating expenses	20,199	26,521
Loss from operations	(20,199)	(26,521)
Other income (expense):
Interest income	7,130	4,979
Investment advisory fees	(265)	(230)
Change in fair value of warrant liability	(1,459)	142
Net (loss) gain on marketable securities	1	(96)
Total other income (expense), net	5,407	4,795
Loss before income taxes	(14,792)	(21,726)
Provision for income taxes	0	0
Net loss	$ (14,792)	$ (21,726)
Net loss per share attributable to common stockholders, basic	$ (0.07)	$ (0.1)
Net loss per share attributable to common stockholders, diluted	$ (0.07)	$ (0.1)
Weighted average common shares outstanding, basic	219,048	218,741
Weighted average common shares outstanding, diluted	219,048	218,741
Comprehensive loss:
Net loss	$ (14,792)	$ (21,726)
Other comprehensive loss, net of taxes:
Unrealized gain (loss) on available-for-sale securities, net	(1,350)	2,588
Comprehensive loss	$ (16,142)	$ (19,138)

NUVB Balance Sheet

2024-03-31

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 34,510	$ 42,649
Prepaid expenses and other current assets	6,796	1,519
Marketable securities	562,466	568,564
Interest receivable on marketable securities	4,283	3,702
Total current assets	608,055	616,434
Property and equipment, net	686	717
Lease security deposit	141	141
Operating lease right-of-use assets	3,168	3,605
Other non-current assets	1,075	587
Total assets	613,125	621,484
Current liabilities:
Accounts payable	2,436	2,209
Current operating lease liabilities	2,023	1,972
Accrued expenses	11,303	9,793
Total current liabilities	15,762	13,974
Warrant liability	1,812	353
Non-current operating lease liabilities	1,509	2,035
Total liabilities	19,083	16,362
Commitments and contingencies (Note 9)
Stockholders' equity
Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000 (Class A 1,000,000,000, Class B 60,000,000) shares authorized as of March 31, 2024 and December 31, 2023, 219,083,219 (Class A 218,083,219, Class B 1,000,000) and 219,046,219 (Class A 218,046,219, Class B 1,000,000) shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	952,807	947,745
Accumulated deficit	(357,596)	(342,804)
Accumulated other comprehensive income	(1,169)	181
Total stockholders' equity	594,042	605,122
Total liabilities and stockholders' equity	$ 613,125	$ 621,484

About Nuvation Bio Inc.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

CEO	Dr. David T. Hung M.D.
WEBSITE	nuvationbio.com
INDUSTRY	Biotechnology
EMPLOYEES	54

Nuvation Bio Inc. Frequently Asked Questions

What is the ticker symbol for Nuvation Bio Inc.? What does NUVB stand for in stocks?

NUVB is the stock ticker symbol of Nuvation Bio Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nuvation Bio Inc. (NUVB)?

As of Fri May 17 2024, market cap of Nuvation Bio Inc. is 820.61 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NUVB stock?

You can check NUVB's fair value in chart for subscribers.

What is the fair value of NUVB stock?

You can check NUVB's fair value in chart for subscribers. The fair value of Nuvation Bio Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nuvation Bio Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NUVB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nuvation Bio Inc. a good stock to buy?

The fair value guage provides a quick view whether NUVB is over valued or under valued. Whether Nuvation Bio Inc. is cheap or expensive depends on the assumptions which impact Nuvation Bio Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NUVB.

What is Nuvation Bio Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, NUVB's PE ratio (Price to Earnings) is -11.92 and Price to Sales (PS) ratio is 30.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NUVB PE ratio will change depending on the future growth rate expectations of investors.